Teva-Handok acquires approval of ‘CINQAIR,’ biologic for treatment of severe asthma patients
Teva-Handok(CEO Sun-Dong Park) announced that ‘CINQAIR(generic name: reslizumab),’ a new monoclonal antibody injection for the treatment of asthma, acquired approval from the Ministry of Food and Drug Safety on the 4th.
CINQAIR is a monoclonal antibody(IgG4 kappa) targeting interleukin-5, a cyt...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.